Conference item icon

Conference item

Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV).

Publication status:
Published

Actions

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author


Host title:
JOURNAL OF CLINICAL ONCOLOGY
Volume:
23
Issue:
16
Pages:
213S-213S
Publication date:
2005-06-01
ISSN:
0732-183X


Pubs id:
pubs:175248
UUID:
uuid:02b05d66-3b14-46c7-b794-73d5caffe769
Local pid:
pubs:175248
Source identifiers:
175248
Deposit date:
2012-12-19
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP